Overall verdict
Neutral
6.2/10
1-year performance
+7.22%
Score breakdown
Up 7.2% over 1 year, 86% of the 52-week range.
Strongest: Shareholder return 7.9/10. Weakest: Valuation 4.7/10.
30 analysts, target +0.0% vs the price.
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients in the United States, Ireland, and internationally. It operates through three segments: The Cardiovascular Portfolio, Neuroscience Portfolio, and Medical Surgical Portfolio. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves, left atrial appendage exclusion systems, extracorporeal membrane oxygenation (ECMO) systems and percutaneous coronary intervention products, percutaneous angioplasty balloons, and endovenous products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name.
This segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists, and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat diseases and conditions, and patient monitoring and airway management products, as well as insulin pumps and consumables, continuous glucose monitoring systems, and sensors. Medtronic plc was founded in 1949 and is headquartered in Galway, Ireland.
Sector
Health Care
Industry
Health Care Equipment and Supplies
Primary listing
Nyse
Ireland
CEO
Mr. Geoffrey Straub Martha
Founded
1949
Employees
95 000
Revenue / employee
382 779 USD
Next earnings
November 24, 2026
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
106.33 USD
52-week low
73.31 USD
1-year performance
7.22%
Rising
Year-to-date performance
6.06%
Rising
Drawdown
-4.20%
Near its high
Position in the 52-week range
86% of range
Against the world ETF
Over 26 years, from December 2000 to October 2026, the share did not clearly beat the world ETF once risk is accounted for. It earned less, while shaking 1.5 times harder.
$10,000 placed at the end of December 2000 are worth today
| Medtronic | $26,502 |
| World ETF | $65,117 |
| S&P 500 | $91,204 |
| Risk-free placement | $15,894 |
The risk
- Shaking:the share moves 1.5 times as much as the world ETF.
- Worst fall:-48 % between December 2000 and March 2009. $10,000 placed at the top fell to $5,208. The world ETF, at worst: -53 %. Back to its high in 51 months.
Medtronic earned less than the world ETF since 2000
Value of $10,000 placed at the end of December 2000, dividends reinvested, in dollars
- Medtronic: $26,502
- World ETF: $65,117
- S&P 500: $91,204
- Risk-free placement: $15,894
Based on past performance. This is not a recommendation.
Range: 95.77 USD - 99.02 USD (3 methods agree)
The price implies growth of 5.79% per year; the company grows at 6.95%.
Gross margin 60.6%, net margin 13.9%, ROIC 7.0%, ROE 10.7%.
Net margin
13.94%
Exceptional
Sector 9.11%|S&P 13.40%
Gross margin
60.56%
Fair
Return on equity (ROE)
10.66%
Exceptional
Sector 7.42%|S&P 17.06%
Return on invested capital (ROIC)
6.98%
Fair
Free cash flow margin (FCF)
16.33%
Exceptional
Profit-to-cash conversion (FCF conversion)
1.17x
High
Margin stability
1.9 pts
Very steady
Revenue to net income
Growth
7.5/10Revenue up 13.7% over 1 year, 3.8% a year over 5, EPS 7.0% a year over 5.
Revenue (trailing 12 months)
37.5Md USD
Revenue growth (1y)
13.73%
Strong
Revenue growth (3y)
16.45%
Solid
EPS growth (1y)
41.57%
Hyper-growth
EPS CAGR (5y)
6.95%
Low
EPS revisions (3 months)
0.44%
Revised up
Valuation
4.7/10P/E 25.1x, forward P/E 22.1x, EV/EBITDA 15.9x, PEG 3.61. The multiple sits in the 49th percentile of its own 5-year history.
P/E (TTM)
25.1x
Fair
Sector 29.3x|S&P 23.6x
Forward P/E
22.1x
Fair
EV / EBITDA
15.9x
Fair
Sector 14.2x|S&P 15.5x
PEG
3.61
Very expensive
Sector 1.25|S&P 0.91
Fair value (reverse DCF)
97.39 USD
Fairly priced
P/E vs its own 5-year history
among the 49% lowest valuations
In line with its history
Market cap
130Md USD
Financial strength
7.2/10Cash covers 31.3% of the debt, net debt/EBITDA 2.0x.
Net debt / EBITDA
2.0x
Tight
Gearing (net debt / equity)
38.02%
Solid
Cash
8.8Md USD
Cash / market cap
6.77%
Tight
Cash / total debt
31.33%
Solid
Interest coverage
9.4x
Solid
Net debt
19.3Md USD
Equity
50.9Md USD
Closed daily candles, 2 years
Last close on November 10, 2026: 101.59 USD
- MM2097.41
- MM5093.16
- MM20088.25
- RSI 1461.9
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
-0.12%
200-day average slope, 3 months
-1.73%
50-day average slope, 1 month
+3.24%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
2.15 % per day
Volatility change
+25.35%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2027 | 4.62 (11) | 5.98 (30) | 38 971 (28) | 10 886 (10) | 6 009 (10) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of November 9, 2026.
Same sub-industry: 187 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | SYK | 6.5 | 6.1 | 121Md USD | 34.0x | 13.8 % | 7.6 % | 9.7 % | 1.7x | 3.8 % | -10.5 % | ||
| 2 | IDXX | 6.3 | 5.7 | 55.4Md USD | 47.4x | 25.4 % | 9.9 % | 54.9 % | 0.5x | 2.3 % | -1.2 % | ||
| 3 | ISRG | 6.2 | 5.5 | 156Md USD | 54.4x | 25.5 % | 21.7 % | 18.0 % | -1.6x | 2.3 % | -21.8 % | ||
| 4 | MDT | 6.2 | 6.7 | 130Md USD | 25.1x | 13.9 % | 13.7 % | 7.0 % | 2.0x | 4.7 % | 7.2 % | ||
| 5 | ABT | 6.0 | 5.2 | 189Md USD | 40.3x | 9.8 % | 14.5 % | 6.6 % | 0.5x | 3.6 % | -13.7 % | ||
| 6 | EW | 5.9 | 5.1 | 60.8Md USD | 61.6x | 14.9 % | 10.5 % | 8.9 % | -2.0x | 2.3 % | 25.3 % | ||
| 7 | BSX | 5.6 | 6.4 | 65.4Md USD | 19.1x | 16.6 % | 1.4 % | 9.8 % | 1.8x | 5.1 % | -55.5 % | ||
| 8 | BDX | 5.5 | 5.3 | 58.4Md USD | 51.8x | 7.4 % | -10.5 % | 3.6 % | 2.9x | 4.6 % | 49.4 % | ||
| 9 | SHL | 5.3 | 5.3 | 53.1Md USD | 22.0x | 9.4 % | 7.3 % | 7.3 % | 2.8x | 4.3 % | 0.0 % |
